Department of Hematology, Changhai Hospital, Second Military Medical University, Shanghai, PR China.
J Hematol Oncol. 2009 Jul 30;2:32. doi: 10.1186/1756-8722-2-32.
The response to remission induction in elderly patients with acute myeloid leukemia (AML) remains poor. The purpose of this paper is to evaluate the efficacy and toxicity of a plant alkaloid, homoharringtonine, in combination with cytarabine as an induction therapy for AML in elderly patients (> or =60 years).
Twenty-three patients were treated with the HA regimen consisting of homoharringtonine (2 mg/m2/day for 7 days) and cytarabine (Ara-C, 100 mg/m2/day for 7 days). The overall response rate was 56.5% with complete remission (CR) rate of 39.1% and partial remission of 17.4%. There was no early death in this cohort of patients. The estimated median overall survival (OS) time of all patients was (12.0 +/- 3.0) months. The estimated OS time of the CR patients was 15 months. The estimated one-year OS rate of all patients treated with HA protocol was (49.3 +/- 13.5) %. The estimated one-year OS rate of the CR patients was (62.5 +/- 17.1) %.
HA is a suitable induction regimen for elderly patients with AML, with relatively low toxicity and reasonable response rate.
老年急性髓系白血病（AML）患者对缓解诱导治疗的反应仍较差。本文旨在评估植物生物碱高三尖杉酯碱（homoharringtonine）联合阿糖胞苷（cytarabine）作为老年（≥60 岁）AML 患者诱导治疗的疗效和毒性。
23 例患者接受了 HA 方案治疗，该方案由高三尖杉酯碱（2 mg/m2/天，连用 7 天）和阿糖胞苷（Ara-C，100 mg/m2/天，连用 7 天）组成。总体缓解率为 56.5%，完全缓解（CR）率为 39.1%，部分缓解率为 17.4%。该患者队列中无早期死亡。所有患者的估计中位总生存期（OS）时间为（12.0±3.0）个月。CR 患者的估计 OS 时间为 15 个月。接受 HA 方案治疗的所有患者的估计 1 年 OS 率为（49.3±13.5）%。CR 患者的估计 1 年 OS 率为（62.5±17.1）%。
HA 是老年 AML 患者的一种合适的诱导方案，具有相对较低的毒性和合理的缓解率。
